Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.

PAX5 水平的差异会促进恶性 B 细胞浸润、进展和耐药性，并预测 MCL 患者的预后不良，且与 CCND1 无关